| For: | Zerem E, Kunosic S, Kurtcehajic A, Zerem D, Zerem O. Bile acids in metabolic dysfunction-associated steatotic liver disease. World J Hepatol 2025; 17(8): 108606 [PMID: 40901599 DOI: 10.4254/wjh.v17.i8.108606] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v17/i8/108606.htm |
| Number | Citing Articles |
| 1 |
Ina Bergheim, Jean Francois Cadranel, Jianguo Chen, Wenxing Ding, Robert Eferl, Carmen Garcia-Ruiz, Hartmut Jaeschke, Firouzeh Kazerouni, Amedeo Lonardo, Derek A. Mann, Nahum Méndez-Sánchez, Camelia Mokhtari, Han Moshage, Chiara Raggi, Pavel Strnad, Oren Tirosh, Honoré Tegwende Zougmore, Jose C Fernandez-Checa. Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment. Exploration of Digestive Diseases 2026; 5 doi: 10.37349/edd.2026.1005110
|
| 2 |
Sergejs Lobanovs, Maksims Jakovenko, Jeļena Ivanova, Jekaterina Nagaiceva, Jurijs Čižovs, Dmitrijs Bļizņuks. Metabolic dysfunction-associated steatotic liver disease as a systemic disorder: extrahepatic manifestations and the need for data-driven phenotyping. Frontiers in Endocrinology 2026; 17 doi: 10.3389/fendo.2026.1873215
|
| 3 |
Jung Woo Eun, Jae Youn Cheong, Soon Sun Kim. Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: a narrative review of pathophysiology, diagnostic value, and therapeutic approaches. Journal of the Korean Medical Association 2026; 69(8) doi: 10.5124/jkma.26.0074
|
| 4 |
Yingchun Liang, Shuxin Si, Ruicheng Gao, Bohan Lin, Yong Wei, Zhong Wu, Jinbei Huang, Zijian Zhou. Multi-omics reveals that chenodeoxycholic acid promotes calcium oxalate kidney stone formation by targeting catalase. The Journal of Nutritional Biochemistry 2026; 155 doi: 10.1016/j.jnutbio.2026.110379
|
| 5 |
Yan Li, Yuyuan Hu, Yuan He, Yuhang Yang, Dingwen Xue, Erkui Xue, Jinghan Jia, Wei Zhang, Jinxi Wang. Loss of immunometabolic adaptability in MASH: gut-derived signals drive macrophage reprogramming and fibrosis. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1793092
|
| 6 |
Mirjana Grocic, Madison Nguyen, Arun J. Sanyal. Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH). Diabetes, Obesity and Metabolism 2026; 28(S2) doi: 10.1111/dom.70662
|
| 7 |
Guangwen Cao, Haonan Zhao, Guo Lin, Junxiu Chen, Cong Gao, Nahum Méndez-Sánchez, Fei Gao, Xingshun Qi. Clinical Relevance of Bile Acid and Bile Acid-Related Therapy in Liver Cirrhosis: A Review. Advances in Therapy 2026; doi: 10.1007/s12325-026-03696-z
|
| 8 |
Ling-Ying Yu, Xian-Feng Zhang. Beyond efficacy: Insights from the norursodeoxycholic acid phase III trial in metabolic dysfunction-associated steatotic liver disease. World Journal of Hepatology 2026; 18(8): 117543 doi: 10.4254/wjh.117543
|
| 9 |
Huiru Liu, Songsong Wang, Na Wang, Fang Wang, Jin Ren, Zirong Zhou, Kairui Liu, Xinyan Wang, Yubo Li, Chunsheng Fu, Liwen Han. Mechanisms and key active ingredients of HeDan capsules in ameliorating MASLD via bile acid metabolism regulation. Journal of Ethnopharmacology 2026; 366 doi: 10.1016/j.jep.2026.121639
|
| 10 |
Lu Yu, Liping Wang, Fangchao Hu, Liyang Liu, Ziyun Wu. Development of a short-term mouse model of early MASLD for non-invasive pathophysiological tracking via urinary metabolomics and micro-CT. Life Sciences 2026; 402 doi: 10.1016/j.lfs.2026.124540
|
| 11 |
Yapeng Zhang, Haoran Xu, Hede Zou, Wei Lin, Wenkang Chen, Jiayou Zhao. The Liver–Testis Axis: Molecular Mechanisms and Clinical Implications. International Journal of Molecular Sciences 2026; 27(13) doi: 10.3390/ijms27135873
|
| 12 |
Yue Zhu, Jishuang San, Guangyi Ouyang, Yunheng Liu, Weiwei Li, Jiancheng Yang, Gaofeng Wu. Taurocholic acid attenuates hepatic inflammation in MASH and modulates the PPARγ/NF-κB axis. European Journal of Pharmacology 2026; 1036 doi: 10.1016/j.ejphar.2026.179395
|